Literature DB >> 16908743

Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1.

Chad R Heatwole1, Jill Miller, Bill Martens, Richard T Moxley.   

Abstract

BACKGROUND: Myotonic dystrophy type 1 (DM1) is the most prevalent form of adult muscular dystrophy worldwide. Although well known for the classic manifestations of myotonia, weakness, and early cataracts, it has broad effects on multiple organ systems.
OBJECTIVE: To analyze and compile the laboratory abnormalities of 126 adult patients with DM1.
DESIGN: Laboratory data obtained before treatment were compiled and include values for 45 different laboratory tests and 2860 total studies.
SETTING: University hospital. PATIENTS: One hundred twenty-six medically healthy, mild to moderately affected, ambulatory patients with DM1 and good venous access enrolled in one of 12 major DM1 clinical trials at a university hospital from 1975 to 2005.
RESULTS: Of the 2860 laboratory studies, results for 470 (16.4%) were outside their reference ranges. Of the 45 types of laboratory tests studied, 41 demonstrated abnormal findings. The relative frequency of an abnormally elevated laboratory value was greater than 50% in several tests, including levels of hemoglobin A(1c), follicle-stimulating hormone, luteinizing hormone in men, and gamma-glutamyltransferase and creatine kinase in women. In addition, levels of lactate dehydrogenase in men and hemoglobin in women were abnormally high or low in more than 50% of the test results evaluated.
CONCLUSION: There is a high frequency of abnormal laboratory values in DM1 that may form a basis for early screening and monitoring and provide insight into the spectrum of tissues involved in this disease.

Entities:  

Mesh:

Year:  2006        PMID: 16908743     DOI: 10.1001/archneur.63.8.1149

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  11 in total

1.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 2.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

3.  Intrinsically cell-penetrating multivalent and multitargeting ligands for myotonic dystrophy type 1.

Authors:  JuYeon Lee; Yugang Bai; Ullas V Chembazhi; Shaohong Peng; Kevin Yum; Long M Luu; Lauren D Hagler; Julio F Serrano; H Y Edwin Chan; Auinash Kalsotra; Steven C Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-11       Impact factor: 11.205

4.  Laboratory abnormalities in patients with myotonic dystrophy type 2.

Authors:  Chad Heatwole; Nicholas Johnson; Bradley Goldberg; William Martens; Richard Moxley
Journal:  Arch Neurol       Date:  2011-09

5.  Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Authors:  Chad Heatwole; Rita Bode; Nicholas Johnson; Christine Quinn; William Martens; Michael P McDermott; Nan Rothrock; Charles Thornton; Barbara Vickrey; David Victorson; Richard Moxley
Journal:  Neurology       Date:  2012-07-11       Impact factor: 9.910

6.  Non-Alcoholic Steatohepatitis in Myotonic Dystrophy: DMPK Gene Mutation, Insulin Resistance and Development of Steatohepatitis.

Authors:  Rishi R Bhardwaj; Andrea Duchini
Journal:  Case Rep Gastroenterol       Date:  2010-03-17

7.  Hormonal and metabolic gender differences in a cohort of myotonic dystrophy type 1 subjects: a retrospective, case-control study.

Authors:  M Spaziani; A Semeraro; E Bucci; F Rossi; M Garibaldi; M A Papassifachis; C Pozza; A Anzuini; A Lenzi; G Antonini; A F Radicioni
Journal:  J Endocrinol Invest       Date:  2019-11-30       Impact factor: 4.256

8.  Cell membrane integrity in myotonic dystrophy type 1: implications for therapy.

Authors:  Anchel González-Barriga; Julia Kranzen; Huib J E Croes; Suzanne Bijl; Walther J A A van den Broek; Ingeborg D G van Kessel; Baziel G M van Engelen; Judith C T van Deutekom; Bé Wieringa; Susan A M Mulders; Derick G Wansink
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

9.  High Prevalence and Gender-Related Differences of Gastrointestinal Manifestations in a Cohort of DM1 Patients: A Perspective, Cross-Sectional Study.

Authors:  Alessia Perna; Daria Maccora; Salvatore Rossi; Tommaso Filippo Nicoletti; Maria Assunta Zocco; Vittorio Riso; Anna Modoni; Antonio Petrucci; Venanzio Valenza; Antonio Grieco; Luca Miele; Gabriella Silvestri
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

10.  miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1.

Authors:  Demetris Koutalianos; Andrie Koutsoulidou; Chrystalla Mytidou; Andrea C Kakouri; Anastasis Oulas; Marios Tomazou; Tassos C Kyriakides; Marianna Prokopi; Konstantinos Kapnisis; Nikoletta Nikolenko; Chris Turner; Anna Lusakowska; Katarzyna Janiszewska; George K Papadimas; Constantinos Papadopoulos; Evangelia Kararizou; George M Spyrou; Geneviève Gourdon; Eleni Zamba Papanicolaou; Grainne Gorman; Andreas Anayiotos; Hanns Lochmüller; Leonidas A Phylactou
Journal:  Mol Ther Methods Clin Dev       Date:  2021-09-14       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.